View Future GrowthSanten Pharmaceutical 過去の業績過去 基準チェック /46Santen Pharmaceuticalは、平均年間31.7%の収益成長を遂げていますが、 Pharmaceuticals業界の収益は、年間 成長しています。収益は、平均年間9.7% 3.4%収益成長率で 成長しています。 Santen Pharmaceuticalの自己資本利益率は12.7%であり、純利益率は12.8%です。主要情報31.66%収益成長率35.19%EPS成長率Pharmaceuticals 業界の成長5.95%収益成長率3.41%株主資本利益率12.69%ネット・マージン12.81%前回の決算情報31 Mar 2026最近の業績更新お知らせ • May 09Santen Pharmaceutical Co., Ltd. to Report Fiscal Year 2026 Results on May 12, 2026Santen Pharmaceutical Co., Ltd. announced that they will report fiscal year 2026 results on May 12, 2026お知らせ • Dec 02Santen Pharmaceutical Co., Ltd. to Report Q3, 2026 Results on Feb 05, 2026Santen Pharmaceutical Co., Ltd. announced that they will report Q3, 2026 results on Feb 05, 2026お知らせ • Sep 01Santen Pharmaceutical Co., Ltd. to Report Q2, 2026 Results on Nov 06, 2025Santen Pharmaceutical Co., Ltd. announced that they will report Q2, 2026 results on Nov 06, 2025お知らせ • Jun 06Santen Pharmaceutical Co., Ltd. to Report Q1, 2026 Results on Aug 07, 2025Santen Pharmaceutical Co., Ltd. announced that they will report Q1, 2026 results on Aug 07, 2025お知らせ • Mar 06Santen Pharmaceutical Co., Ltd. to Report Fiscal Year 2025 Results on May 13, 2025Santen Pharmaceutical Co., Ltd. announced that they will report fiscal year 2025 results on May 13, 2025お知らせ • Dec 03Santen Pharmaceutical Co., Ltd. to Report Q3, 2025 Results on Feb 06, 2025Santen Pharmaceutical Co., Ltd. announced that they will report Q3, 2025 results on Feb 06, 2025すべての更新を表示Recent updatesお知らせ • May 12Santen Pharmaceutical Co., Ltd., Annual General Meeting, Jun 23, 2026Santen Pharmaceutical Co., Ltd., Annual General Meeting, Jun 23, 2026.お知らせ • May 09Santen Pharmaceutical Co., Ltd. to Report Fiscal Year 2026 Results on May 12, 2026Santen Pharmaceutical Co., Ltd. announced that they will report fiscal year 2026 results on May 12, 2026お知らせ • Jan 08RVL Pharmaceuticals Announces Santen Obtains Manufacturing and Marketing Approval in Japan for UPNEEQ ®? Mini Ophthalmic Solution 0.1%RVL Pharmaceuticals Inc. and its affiliates announced Santen Pharmaceutical Co., Ltd. ("Santen"), a leading ophthalmology company has obtained the manufacturing and marketing approval in Japan for UPNEEQ®? Mini Ophthalmic Solution 0.1% (generic name:oxymetazoline hydrochloride; development code: STN1013800; hereinafter the product), a treatment for acquired blepharoptosis (low-lying eyelids). This milestone expands access in Japan to the first approved non-invasive treatment for blepharoptosis, where treatment options have primarily been limited to surgical procedures. In the U.S. market, Upneeq®? is the first and only FDA-approved prescription eye drop for acquired blepharoptOS (low-lying eyelids), and continues to demonstrate strong patient satisfaction, increased adoption, and channel diversification. The superiority of the product was demonstrated in the primary endpoint - a change from baseline at 2 hours after administration in MRD-1 (Marginal Reflex Distance-1, the margin between the upper eyelid and the center of the pupil) at Day 14 after the start of treatment--in the once-daily group versus the placebo eye drop group. In addition, an exploratory analysis showed that improvement in MRD-1 persisted for more than 8 hours after instillation. No serious adverse effects or adverse effects leading to treatment discontinuation were observed during the study. In the Phase 3 clinical trial in Japan (once-daily instillation for 6 months), no trend toward strengthening of the eyelid-lifting effect or rebound effect was observed. In this clinical study, MRD-1 was defined as the distance from the center of the pupil to the upper eyelid margin, as determined from anterior segment photographs. Upneeq®? (oxymetazoline hydrochlorides ophthalmic solution), 0.1% is a prescription eyedrop used to treat acquired blepharoptosis ("low-lying lids") in adults. The product was approved in the US by the FDA in July 2020. Low-lying lids may be related to conditions such as stroke and/or brain aneurysm, Horner syndrome, myasthenia gravis, loss of the ability to move eye muscles, eye infection and eye tumors. Tell your doctor if you have any of these conditions. UPNEEQ is a type of medication that may affect blood pressure. Upneeq®? activates a muscle in the eyelids, lifting the lid for a more open and awake look. One drop daily is clinically proven to provide visible results in as fast as 5 minutes and lasts up to 8 hours. In July 2020, Osmotica Pharmaceuticals plc (due to a company name change, currently known as RVL Pharmaceuticals Inc.), entered into an exclusive license agreement with Santen, covering the continued development, registration, and commercialization rights for RVL-1201, a 0.1% oxymetazoline hydrochloride ophthalmic solution, in Japan and certain other international markets. Santen has been developing the product as STN1013800.お知らせ • Dec 02Santen Pharmaceutical Co., Ltd. to Report Q3, 2026 Results on Feb 05, 2026Santen Pharmaceutical Co., Ltd. announced that they will report Q3, 2026 results on Feb 05, 2026お知らせ • Nov 07Santen Pharmaceutical Co., Ltd. Receives UK Approval for Ryjunea®? (Low-Dose Atropine 0.1 Mg/L) to Slow Progression of Childhood MyopiaSanten announced that the UK Medicines and Healthcare products Regulatory Agency (MHRA) has approved Ryjunea®? (low-dose atropine 0.1 mg/ml), the first licensed treatment in the UK to slow the progression of myopia in children. The approval follows the European Commission authorisation and the first launch in Germany earlier this year, with additional launches in Europe to follow. Short-sightedness is rising fast among children in the UK, where many children now live with myopia, more than double the number from 50 years ago. Increased screen time, less outdoor activity, and intensive near work are putting a growing strain on young eyes. Globally, approximately one in three children and adolescents are expected to be affected by 2050. The first signs of myopia often appear in daily life: a child squinting to read the board, moving closer to the TV, or struggling to recognise faces at a distance. Myopia can affect learning, confidence, and participation in school and play. Early interventions are key to slowing progression and supporting children's eye health and wellbeing. Childhood myopia increases the risk of severe eye disease later in life. "A comprehensive approach, combining lifestyle habits, optical correction, and approved medical options, gives children the best chance to support healthy vision into adulthood." With over 135 years of experience in eye health, Santen is committed to advancing early intervention and collaboration in paediatric myopia, for happier lives and brighter futures. Ryjunea®? is a registered trademark of Santen Pharmaceutical Co., Ltd. Ryjunea®®? is indicated for slowing the progression of myopia in paediatric patients. Treatment may be initiated in children aged 3-14 years with a progression rate of 0.5 D or more per year and a severity of -0.5 D to -6.0 D. It is backed by the Phase III STAR study, showing that Ryjunea®? significantly reduced the annual progression of myopia with an acceptable safety and tolerability profile. As a low-dose atropine eye drop, administered once daily at bedtime, it provides a convenient way to manage myopia that integrates easily into a child's routine. The product is licensed from Sydnexis Inc. to Santen's Switzerland-based affiliate, Santen SA, for registration and commercialisation across Europe, the Middle East, and Africa (EMEA). It has received market authorisation from the European Commission on June 2, and now from the UK Medicines and Healthcare Products Regulatory Agency (MHRA) on October 30.お知らせ • Sep 01Santen Pharmaceutical Co., Ltd. to Report Q2, 2026 Results on Nov 06, 2025Santen Pharmaceutical Co., Ltd. announced that they will report Q2, 2026 results on Nov 06, 2025お知らせ • Jun 06Santen Pharmaceutical Co., Ltd. to Report Q1, 2026 Results on Aug 07, 2025Santen Pharmaceutical Co., Ltd. announced that they will report Q1, 2026 results on Aug 07, 2025お知らせ • May 15Santen Pharmaceutical Co., Ltd. (TSE:4536) announces an Equity Buyback for 19,800,000 shares, representing 5.8% for ¥35,000 million.Santen Pharmaceutical Co., Ltd. (TSE:4536) announces a share repurchase program. Under the program, the company will repurchase up to 19,800,000 of its common shares, representing 5.8% of its outstanding shares for ¥35,000 million. The program is aimed at enhancing shareholder returns and further improving capital efficiency. The plan will be valid up to November 5, 2025. As on November 5, 2025, the company had 341,423,368 shares outstanding and 632,186 shares in its treasury.お知らせ • May 14Santen Pharmaceutical Co., Ltd., Annual General Meeting, Jun 24, 2025Santen Pharmaceutical Co., Ltd., Annual General Meeting, Jun 24, 2025.お知らせ • Mar 06Santen Pharmaceutical Co., Ltd. to Report Fiscal Year 2025 Results on May 13, 2025Santen Pharmaceutical Co., Ltd. announced that they will report fiscal year 2025 results on May 13, 2025お知らせ • Dec 03Santen Pharmaceutical Co., Ltd. to Report Q3, 2025 Results on Feb 06, 2025Santen Pharmaceutical Co., Ltd. announced that they will report Q3, 2025 results on Feb 06, 2025お知らせ • Nov 07Santen Pharmaceutical Co., Ltd. (TSE:4536) announces an Equity Buyback for 5,000,000 shares, representing 1.44% for ¥10,000 million.Santen Pharmaceutical Co., Ltd. (TSE:4536) announces a share repurchase program. Under the program, the company will repurchase up to 5,000,000 of its common shares, representing 1.44% of its outstanding shares for ¥10,000 million. The purpose of the program is to enhance capital efficiency and improve return of profits based on a comprehensive consideration of factors such as profitability improvement and business environment in accordance with the capital allocation policy in the medium-term management plan. The repurchased shares will be cancelled. The plan will be valid up to March 21, 2025. As on October 31, 2024, the company had 347,002,868 shares outstanding and 17,019,386 shares in its treasury.お知らせ • Sep 04Santen Pharmaceutical Co., Ltd. to Report Q2, 2025 Results on Nov 07, 2024Santen Pharmaceutical Co., Ltd. announced that they will report Q2, 2025 results on Nov 07, 2024お知らせ • Jun 02Santen Pharmaceutical Co., Ltd. to Report Q1, 2025 Results on Aug 06, 2024Santen Pharmaceutical Co., Ltd. announced that they will report Q1, 2025 results on Aug 06, 2024お知らせ • May 11Santen Pharmaceutical Co., Ltd., Annual General Meeting, Jun 25, 2024Santen Pharmaceutical Co., Ltd., Annual General Meeting, Jun 25, 2024.お知らせ • May 10+ 3 more updatesSanten Pharmaceutical Co., Ltd. (TSE:4536) announces an Equity Buyback for 21,110,000 shares, representing 5.81% for ¥38,000 million.Santen Pharmaceutical Co., Ltd. (TSE:4536) announces a share repurchase program. Under the program, the company will repurchase up to 21,110,000 of its common shares, representing 5.81% of its outstanding shares for ¥38,000 million. The purpose of the program is to enhance capital efficiency and improve return of profits based on a comprehensive consideration of factors such as profitability improvement and business environment in accordance with the capital allocation policy in the medium-term management plan. The repurchased shares will be cancelled. The plan will be valid up to November 6, 2024. As on March 31, 2024, the company had 363,258,785 shares outstanding and 737,469 shares in its treasury.お知らせ • Mar 02Santen Pharmaceutical Co., Ltd. to Report Fiscal Year 2024 Results on May 09, 2024Santen Pharmaceutical Co., Ltd. announced that they will report fiscal year 2024 results on May 09, 2024お知らせ • Feb 09Santen Pharmaceutical Co., Ltd. Revises Dividend Guidance for the Fiscal Year Ending March 31, 2024Santen Pharmaceutical Co., Ltd. Revised Dividend guidance for the Fiscal Year Ending March 31, 2024. For the year, the company expects dividend of JPY 17.00 per share against previous guidance of JPY 16.00 per share.お知らせ • Dec 02Santen Pharmaceutical Co., Ltd. to Report Q3, 2024 Results on Feb 08, 2024Santen Pharmaceutical Co., Ltd. announced that they will report Q3, 2024 results on Feb 08, 2024お知らせ • Sep 21Santen Pharmaceutical Co., Ltd. Revises Consolidated Earnings Forecasts for the Fiscal Year Ending March 31, 2024Santen Pharmaceutical Co., Ltd. revised consolidated earnings forecasts for the fiscal year ending March 31, 2024. For the year, on a core basis, the company expects revenue of ¥285,000 million, core operating profit of ¥50,000 million, core net profit for the year of ¥37,500 million and basic core earnings per share of ¥102.47 compared to the previous guidance of revenue of ¥273,000 million, core operating profit of ¥46,000 million, core net profit for the year of ¥34,500 million and basic core earnings per share of ¥94.27 provided earlier. On IFRS basis, the company expects revenue of ¥285,000 million, operating profit of ¥35,000 million, net profit for the year of ¥25,000 million and basic earnings per share of ¥68.34 compared to the previous guidance of revenue of ¥273,000 million, operating profit of ¥32,000 million, core net profit for the year of ¥22,400 million and basic core earnings per share of ¥61.24 provided earlier.お知らせ • Aug 27Santen Pharmaceutical Co., Ltd. to Report Q2, 2024 Results on Nov 07, 2023Santen Pharmaceutical Co., Ltd. announced that they will report Q2, 2024 results on Nov 07, 2023お知らせ • May 31Santen Pharmaceutical Co., Ltd. to Report Q1, 2024 Results on Aug 03, 2023Santen Pharmaceutical Co., Ltd. announced that they will report Q1, 2024 results on Aug 03, 2023お知らせ • May 12+ 2 more updatesSanten Pharmaceutical Co., Ltd. Announces Year End Dividend for the Year Ended March 31, 2023, Payable on June 28, 2023; Provides Dividend Guidance for the End of Second Quarter and Full Year Ending March 31, 2024Santen Pharmaceutical Co., Ltd. announced year end dividend for the year ended March 31, 2023 of JPY 16.00 per share compared to JPY 16.00 per share a year ago. Start of Distribution of Dividends (Scheduled): June 28, 2023. The company provided dividend guidance for the end of second quarter and full year ending March 31, 2024. For the end of second quarter, the company expects to pay dividend of JPY 16.00 per share compared to JPY 16.00 per share a year ago.For the year, the company expects to pay dividend of JPY 16.00 per share compared to JPY 16.00 per share a year ago.お知らせ • Feb 08Santen Pharmaceutical Co., Ltd. Revises Consolidated and Core Earnings Guidance for the Year Ending March 31, 2023Santen Pharmaceutical Co., Ltd. revised consolidated and core earnings guidance for the year ending March 31, 2023. For the year on consolidated basis, the company revised revenue of JPY 272,000 million compared to previous guidance of JPY 280,000 million. Operating loss of JPY 6,500 million compared to previous guidance operating profit of JPY 4,000 million. Net loss for the year of JPY 15,500 million compared to previous guidance of JPY 5,500 million. Basic loss per share of JPY 40.01 compared to previous guidance of JPY 14.20.For the year on core basis, the company revised revenue of JPY 272,000 million compared to previous guidance of JPY 280,000 million. Core operating profit of JPY 41,000 million compared to previous guidance JPY 45,500 million. Core Net profit for the year of JPY 30,800 million compared to previous guidance of JPY 34,100 million. Core Basic earnings per share of JPY 79.50 compared to previous guidance of JPY 88.04.お知らせ • Dec 18Santen Pharmaceutical Co., Ltd. to Report Q3, 2023 Results on Feb 07, 2023Santen Pharmaceutical Co., Ltd. announced that they will report Q3, 2023 results on Feb 07, 2023お知らせ • May 12Santen Pharmaceutical Co., Ltd., Annual General Meeting, Jun 27, 2023Santen Pharmaceutical Co., Ltd., Annual General Meeting, Jun 27, 2023.収支内訳Santen Pharmaceutical の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。収益と収入の歴史OTCPK:SNPH.F 収益、費用、利益 ( )JPY Millions日付収益収益G+A経費研究開発費31 Mar 26291,62437,36989,57026,18531 Dec 25287,99430,59887,34925,50230 Sep 25291,47931,41483,81325,53030 Jun 25293,97031,49287,09224,60631 Mar 25300,00436,24783,51124,10331 Dec 24301,90527,49487,22323,98130 Sep 24302,56326,12486,31023,89930 Jun 24304,34726,85387,58324,61931 Mar 24301,96526,63487,27025,41631 Dec 23302,08427,714133,319-3,47430 Sep 23295,92826,364134,950-1,80630 Jun 23285,893-11,205135,711-79831 Mar 23279,037-14,955134,072031 Dec 22270,242-8,195125,7892,87930 Sep 22266,413-9,133123,2541,92930 Jun 22266,80426,533119,59097931 Mar 22266,25727,212120,610031 Dec 21263,6205,056121,0881,15030 Sep 21259,4597,319119,9961,21530 Jun 21257,0287,978118,48250431 Mar 21249,6056,826113,586031 Dec 20241,01524,430106,58550030 Sep 20241,68524,279106,419-28930 Jun 20239,98223,404106,103-55831 Mar 20241,55523,616106,599031 Dec 19243,14228,876103,6316230 Sep 19238,45730,721101,96844830 Jun 19236,67931,498101,89455531 Mar 19234,02631,953102,020031 Dec 18229,56031,291101,646-80430 Sep 18228,51234,370101,724-77830 Jun 18225,47733,083101,043631 Mar 18224,94235,24799,926031 Dec 17217,02130,58065,85524,75130 Sep 17212,04125,71763,87224,22430 Jun 17205,03824,75661,89023,24131 Mar 17199,09623,06160,93422,78631 Dec 16196,75423,29959,89821,63630 Sep 16195,24722,31759,53221,05130 Jun 16197,32253,15559,16920,56131 Mar 16195,29153,37358,38219,99031 Dec 15194,19357,72940,10731,76130 Sep 15187,77958,59043,52426,72030 Jun 15176,12427,84246,68122,064質の高い収益: SNPH.Fは 高品質の収益 を持っています。利益率の向上: SNPH.Fの現在の純利益率 (12.8%)は、昨年(12.1%)よりも高くなっています。フリー・キャッシュフローと収益の比較過去の収益成長分析収益動向: SNPH.Fの収益は過去 5 年間で年間31.7%増加しました。成長の加速: SNPH.Fの過去 1 年間の収益成長率 ( 3.1% ) は、5 年間の平均 ( 年間31.7%を下回っています。収益対業界: SNPH.Fの過去 1 年間の収益成長率 ( 3.1% ) はPharmaceuticals業界-5%を上回りました。株主資本利益率高いROE: SNPH.Fの 自己資本利益率 ( 12.7% ) は 低い とみなされます。総資産利益率使用総資本利益率過去の好業績企業の発掘7D1Y7D1Y7D1YPharmaceuticals-biotech 、過去の業績が好調な企業。View Financial Health企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/24 05:28終値2026/03/13 00:00収益2026/03/31年間収益2026/03/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Santen Pharmaceutical Co., Ltd. 8 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。18 アナリスト機関Atsushi SekiBarclaysKoichi MameganoBofA Global ResearchHidemaru YamaguchiCitigroup Inc15 その他のアナリストを表示
お知らせ • May 09Santen Pharmaceutical Co., Ltd. to Report Fiscal Year 2026 Results on May 12, 2026Santen Pharmaceutical Co., Ltd. announced that they will report fiscal year 2026 results on May 12, 2026
お知らせ • Dec 02Santen Pharmaceutical Co., Ltd. to Report Q3, 2026 Results on Feb 05, 2026Santen Pharmaceutical Co., Ltd. announced that they will report Q3, 2026 results on Feb 05, 2026
お知らせ • Sep 01Santen Pharmaceutical Co., Ltd. to Report Q2, 2026 Results on Nov 06, 2025Santen Pharmaceutical Co., Ltd. announced that they will report Q2, 2026 results on Nov 06, 2025
お知らせ • Jun 06Santen Pharmaceutical Co., Ltd. to Report Q1, 2026 Results on Aug 07, 2025Santen Pharmaceutical Co., Ltd. announced that they will report Q1, 2026 results on Aug 07, 2025
お知らせ • Mar 06Santen Pharmaceutical Co., Ltd. to Report Fiscal Year 2025 Results on May 13, 2025Santen Pharmaceutical Co., Ltd. announced that they will report fiscal year 2025 results on May 13, 2025
お知らせ • Dec 03Santen Pharmaceutical Co., Ltd. to Report Q3, 2025 Results on Feb 06, 2025Santen Pharmaceutical Co., Ltd. announced that they will report Q3, 2025 results on Feb 06, 2025
お知らせ • May 12Santen Pharmaceutical Co., Ltd., Annual General Meeting, Jun 23, 2026Santen Pharmaceutical Co., Ltd., Annual General Meeting, Jun 23, 2026.
お知らせ • May 09Santen Pharmaceutical Co., Ltd. to Report Fiscal Year 2026 Results on May 12, 2026Santen Pharmaceutical Co., Ltd. announced that they will report fiscal year 2026 results on May 12, 2026
お知らせ • Jan 08RVL Pharmaceuticals Announces Santen Obtains Manufacturing and Marketing Approval in Japan for UPNEEQ ®? Mini Ophthalmic Solution 0.1%RVL Pharmaceuticals Inc. and its affiliates announced Santen Pharmaceutical Co., Ltd. ("Santen"), a leading ophthalmology company has obtained the manufacturing and marketing approval in Japan for UPNEEQ®? Mini Ophthalmic Solution 0.1% (generic name:oxymetazoline hydrochloride; development code: STN1013800; hereinafter the product), a treatment for acquired blepharoptosis (low-lying eyelids). This milestone expands access in Japan to the first approved non-invasive treatment for blepharoptosis, where treatment options have primarily been limited to surgical procedures. In the U.S. market, Upneeq®? is the first and only FDA-approved prescription eye drop for acquired blepharoptOS (low-lying eyelids), and continues to demonstrate strong patient satisfaction, increased adoption, and channel diversification. The superiority of the product was demonstrated in the primary endpoint - a change from baseline at 2 hours after administration in MRD-1 (Marginal Reflex Distance-1, the margin between the upper eyelid and the center of the pupil) at Day 14 after the start of treatment--in the once-daily group versus the placebo eye drop group. In addition, an exploratory analysis showed that improvement in MRD-1 persisted for more than 8 hours after instillation. No serious adverse effects or adverse effects leading to treatment discontinuation were observed during the study. In the Phase 3 clinical trial in Japan (once-daily instillation for 6 months), no trend toward strengthening of the eyelid-lifting effect or rebound effect was observed. In this clinical study, MRD-1 was defined as the distance from the center of the pupil to the upper eyelid margin, as determined from anterior segment photographs. Upneeq®? (oxymetazoline hydrochlorides ophthalmic solution), 0.1% is a prescription eyedrop used to treat acquired blepharoptosis ("low-lying lids") in adults. The product was approved in the US by the FDA in July 2020. Low-lying lids may be related to conditions such as stroke and/or brain aneurysm, Horner syndrome, myasthenia gravis, loss of the ability to move eye muscles, eye infection and eye tumors. Tell your doctor if you have any of these conditions. UPNEEQ is a type of medication that may affect blood pressure. Upneeq®? activates a muscle in the eyelids, lifting the lid for a more open and awake look. One drop daily is clinically proven to provide visible results in as fast as 5 minutes and lasts up to 8 hours. In July 2020, Osmotica Pharmaceuticals plc (due to a company name change, currently known as RVL Pharmaceuticals Inc.), entered into an exclusive license agreement with Santen, covering the continued development, registration, and commercialization rights for RVL-1201, a 0.1% oxymetazoline hydrochloride ophthalmic solution, in Japan and certain other international markets. Santen has been developing the product as STN1013800.
お知らせ • Dec 02Santen Pharmaceutical Co., Ltd. to Report Q3, 2026 Results on Feb 05, 2026Santen Pharmaceutical Co., Ltd. announced that they will report Q3, 2026 results on Feb 05, 2026
お知らせ • Nov 07Santen Pharmaceutical Co., Ltd. Receives UK Approval for Ryjunea®? (Low-Dose Atropine 0.1 Mg/L) to Slow Progression of Childhood MyopiaSanten announced that the UK Medicines and Healthcare products Regulatory Agency (MHRA) has approved Ryjunea®? (low-dose atropine 0.1 mg/ml), the first licensed treatment in the UK to slow the progression of myopia in children. The approval follows the European Commission authorisation and the first launch in Germany earlier this year, with additional launches in Europe to follow. Short-sightedness is rising fast among children in the UK, where many children now live with myopia, more than double the number from 50 years ago. Increased screen time, less outdoor activity, and intensive near work are putting a growing strain on young eyes. Globally, approximately one in three children and adolescents are expected to be affected by 2050. The first signs of myopia often appear in daily life: a child squinting to read the board, moving closer to the TV, or struggling to recognise faces at a distance. Myopia can affect learning, confidence, and participation in school and play. Early interventions are key to slowing progression and supporting children's eye health and wellbeing. Childhood myopia increases the risk of severe eye disease later in life. "A comprehensive approach, combining lifestyle habits, optical correction, and approved medical options, gives children the best chance to support healthy vision into adulthood." With over 135 years of experience in eye health, Santen is committed to advancing early intervention and collaboration in paediatric myopia, for happier lives and brighter futures. Ryjunea®? is a registered trademark of Santen Pharmaceutical Co., Ltd. Ryjunea®®? is indicated for slowing the progression of myopia in paediatric patients. Treatment may be initiated in children aged 3-14 years with a progression rate of 0.5 D or more per year and a severity of -0.5 D to -6.0 D. It is backed by the Phase III STAR study, showing that Ryjunea®? significantly reduced the annual progression of myopia with an acceptable safety and tolerability profile. As a low-dose atropine eye drop, administered once daily at bedtime, it provides a convenient way to manage myopia that integrates easily into a child's routine. The product is licensed from Sydnexis Inc. to Santen's Switzerland-based affiliate, Santen SA, for registration and commercialisation across Europe, the Middle East, and Africa (EMEA). It has received market authorisation from the European Commission on June 2, and now from the UK Medicines and Healthcare Products Regulatory Agency (MHRA) on October 30.
お知らせ • Sep 01Santen Pharmaceutical Co., Ltd. to Report Q2, 2026 Results on Nov 06, 2025Santen Pharmaceutical Co., Ltd. announced that they will report Q2, 2026 results on Nov 06, 2025
お知らせ • Jun 06Santen Pharmaceutical Co., Ltd. to Report Q1, 2026 Results on Aug 07, 2025Santen Pharmaceutical Co., Ltd. announced that they will report Q1, 2026 results on Aug 07, 2025
お知らせ • May 15Santen Pharmaceutical Co., Ltd. (TSE:4536) announces an Equity Buyback for 19,800,000 shares, representing 5.8% for ¥35,000 million.Santen Pharmaceutical Co., Ltd. (TSE:4536) announces a share repurchase program. Under the program, the company will repurchase up to 19,800,000 of its common shares, representing 5.8% of its outstanding shares for ¥35,000 million. The program is aimed at enhancing shareholder returns and further improving capital efficiency. The plan will be valid up to November 5, 2025. As on November 5, 2025, the company had 341,423,368 shares outstanding and 632,186 shares in its treasury.
お知らせ • May 14Santen Pharmaceutical Co., Ltd., Annual General Meeting, Jun 24, 2025Santen Pharmaceutical Co., Ltd., Annual General Meeting, Jun 24, 2025.
お知らせ • Mar 06Santen Pharmaceutical Co., Ltd. to Report Fiscal Year 2025 Results on May 13, 2025Santen Pharmaceutical Co., Ltd. announced that they will report fiscal year 2025 results on May 13, 2025
お知らせ • Dec 03Santen Pharmaceutical Co., Ltd. to Report Q3, 2025 Results on Feb 06, 2025Santen Pharmaceutical Co., Ltd. announced that they will report Q3, 2025 results on Feb 06, 2025
お知らせ • Nov 07Santen Pharmaceutical Co., Ltd. (TSE:4536) announces an Equity Buyback for 5,000,000 shares, representing 1.44% for ¥10,000 million.Santen Pharmaceutical Co., Ltd. (TSE:4536) announces a share repurchase program. Under the program, the company will repurchase up to 5,000,000 of its common shares, representing 1.44% of its outstanding shares for ¥10,000 million. The purpose of the program is to enhance capital efficiency and improve return of profits based on a comprehensive consideration of factors such as profitability improvement and business environment in accordance with the capital allocation policy in the medium-term management plan. The repurchased shares will be cancelled. The plan will be valid up to March 21, 2025. As on October 31, 2024, the company had 347,002,868 shares outstanding and 17,019,386 shares in its treasury.
お知らせ • Sep 04Santen Pharmaceutical Co., Ltd. to Report Q2, 2025 Results on Nov 07, 2024Santen Pharmaceutical Co., Ltd. announced that they will report Q2, 2025 results on Nov 07, 2024
お知らせ • Jun 02Santen Pharmaceutical Co., Ltd. to Report Q1, 2025 Results on Aug 06, 2024Santen Pharmaceutical Co., Ltd. announced that they will report Q1, 2025 results on Aug 06, 2024
お知らせ • May 11Santen Pharmaceutical Co., Ltd., Annual General Meeting, Jun 25, 2024Santen Pharmaceutical Co., Ltd., Annual General Meeting, Jun 25, 2024.
お知らせ • May 10+ 3 more updatesSanten Pharmaceutical Co., Ltd. (TSE:4536) announces an Equity Buyback for 21,110,000 shares, representing 5.81% for ¥38,000 million.Santen Pharmaceutical Co., Ltd. (TSE:4536) announces a share repurchase program. Under the program, the company will repurchase up to 21,110,000 of its common shares, representing 5.81% of its outstanding shares for ¥38,000 million. The purpose of the program is to enhance capital efficiency and improve return of profits based on a comprehensive consideration of factors such as profitability improvement and business environment in accordance with the capital allocation policy in the medium-term management plan. The repurchased shares will be cancelled. The plan will be valid up to November 6, 2024. As on March 31, 2024, the company had 363,258,785 shares outstanding and 737,469 shares in its treasury.
お知らせ • Mar 02Santen Pharmaceutical Co., Ltd. to Report Fiscal Year 2024 Results on May 09, 2024Santen Pharmaceutical Co., Ltd. announced that they will report fiscal year 2024 results on May 09, 2024
お知らせ • Feb 09Santen Pharmaceutical Co., Ltd. Revises Dividend Guidance for the Fiscal Year Ending March 31, 2024Santen Pharmaceutical Co., Ltd. Revised Dividend guidance for the Fiscal Year Ending March 31, 2024. For the year, the company expects dividend of JPY 17.00 per share against previous guidance of JPY 16.00 per share.
お知らせ • Dec 02Santen Pharmaceutical Co., Ltd. to Report Q3, 2024 Results on Feb 08, 2024Santen Pharmaceutical Co., Ltd. announced that they will report Q3, 2024 results on Feb 08, 2024
お知らせ • Sep 21Santen Pharmaceutical Co., Ltd. Revises Consolidated Earnings Forecasts for the Fiscal Year Ending March 31, 2024Santen Pharmaceutical Co., Ltd. revised consolidated earnings forecasts for the fiscal year ending March 31, 2024. For the year, on a core basis, the company expects revenue of ¥285,000 million, core operating profit of ¥50,000 million, core net profit for the year of ¥37,500 million and basic core earnings per share of ¥102.47 compared to the previous guidance of revenue of ¥273,000 million, core operating profit of ¥46,000 million, core net profit for the year of ¥34,500 million and basic core earnings per share of ¥94.27 provided earlier. On IFRS basis, the company expects revenue of ¥285,000 million, operating profit of ¥35,000 million, net profit for the year of ¥25,000 million and basic earnings per share of ¥68.34 compared to the previous guidance of revenue of ¥273,000 million, operating profit of ¥32,000 million, core net profit for the year of ¥22,400 million and basic core earnings per share of ¥61.24 provided earlier.
お知らせ • Aug 27Santen Pharmaceutical Co., Ltd. to Report Q2, 2024 Results on Nov 07, 2023Santen Pharmaceutical Co., Ltd. announced that they will report Q2, 2024 results on Nov 07, 2023
お知らせ • May 31Santen Pharmaceutical Co., Ltd. to Report Q1, 2024 Results on Aug 03, 2023Santen Pharmaceutical Co., Ltd. announced that they will report Q1, 2024 results on Aug 03, 2023
お知らせ • May 12+ 2 more updatesSanten Pharmaceutical Co., Ltd. Announces Year End Dividend for the Year Ended March 31, 2023, Payable on June 28, 2023; Provides Dividend Guidance for the End of Second Quarter and Full Year Ending March 31, 2024Santen Pharmaceutical Co., Ltd. announced year end dividend for the year ended March 31, 2023 of JPY 16.00 per share compared to JPY 16.00 per share a year ago. Start of Distribution of Dividends (Scheduled): June 28, 2023. The company provided dividend guidance for the end of second quarter and full year ending March 31, 2024. For the end of second quarter, the company expects to pay dividend of JPY 16.00 per share compared to JPY 16.00 per share a year ago.For the year, the company expects to pay dividend of JPY 16.00 per share compared to JPY 16.00 per share a year ago.
お知らせ • Feb 08Santen Pharmaceutical Co., Ltd. Revises Consolidated and Core Earnings Guidance for the Year Ending March 31, 2023Santen Pharmaceutical Co., Ltd. revised consolidated and core earnings guidance for the year ending March 31, 2023. For the year on consolidated basis, the company revised revenue of JPY 272,000 million compared to previous guidance of JPY 280,000 million. Operating loss of JPY 6,500 million compared to previous guidance operating profit of JPY 4,000 million. Net loss for the year of JPY 15,500 million compared to previous guidance of JPY 5,500 million. Basic loss per share of JPY 40.01 compared to previous guidance of JPY 14.20.For the year on core basis, the company revised revenue of JPY 272,000 million compared to previous guidance of JPY 280,000 million. Core operating profit of JPY 41,000 million compared to previous guidance JPY 45,500 million. Core Net profit for the year of JPY 30,800 million compared to previous guidance of JPY 34,100 million. Core Basic earnings per share of JPY 79.50 compared to previous guidance of JPY 88.04.
お知らせ • Dec 18Santen Pharmaceutical Co., Ltd. to Report Q3, 2023 Results on Feb 07, 2023Santen Pharmaceutical Co., Ltd. announced that they will report Q3, 2023 results on Feb 07, 2023
お知らせ • May 12Santen Pharmaceutical Co., Ltd., Annual General Meeting, Jun 27, 2023Santen Pharmaceutical Co., Ltd., Annual General Meeting, Jun 27, 2023.